IL187430A - Derivatives of the affluent carboxylic acid carboxylic acid (sulfoam alkyl) process, their formulation, their pharmaceutical preparation and its use in the preparation of drugs to inhibit factor xa for the effect of blood clotting or fibrinolysis - Google Patents

Derivatives of the affluent carboxylic acid carboxylic acid (sulfoam alkyl) process, their formulation, their pharmaceutical preparation and its use in the preparation of drugs to inhibit factor xa for the effect of blood clotting or fibrinolysis

Info

Publication number
IL187430A
IL187430A IL187430A IL18743007A IL187430A IL 187430 A IL187430 A IL 187430A IL 187430 A IL187430 A IL 187430A IL 18743007 A IL18743007 A IL 18743007A IL 187430 A IL187430 A IL 187430A
Authority
IL
Israel
Prior art keywords
fibrinolysis
medicaments
heteroaryl
amide
derivatives
Prior art date
Application number
IL187430A
Other languages
English (en)
Hebrew (he)
Other versions
IL187430A0 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL187430A0 publication Critical patent/IL187430A0/en
Publication of IL187430A publication Critical patent/IL187430A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL187430A 2005-05-20 2007-11-15 Derivatives of the affluent carboxylic acid carboxylic acid (sulfoam alkyl) process, their formulation, their pharmaceutical preparation and its use in the preparation of drugs to inhibit factor xa for the effect of blood clotting or fibrinolysis IL187430A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010929A EP1724269A1 (en) 2005-05-20 2005-05-20 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
PCT/EP2006/004255 WO2006122661A1 (en) 2005-05-20 2006-05-06 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors

Publications (2)

Publication Number Publication Date
IL187430A0 IL187430A0 (en) 2008-02-09
IL187430A true IL187430A (en) 2013-06-27

Family

ID=35116052

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187430A IL187430A (en) 2005-05-20 2007-11-15 Derivatives of the affluent carboxylic acid carboxylic acid (sulfoam alkyl) process, their formulation, their pharmaceutical preparation and its use in the preparation of drugs to inhibit factor xa for the effect of blood clotting or fibrinolysis

Country Status (25)

Country Link
US (1) US8088925B2 (https=)
EP (2) EP1724269A1 (https=)
JP (1) JP5027802B2 (https=)
KR (1) KR101373533B1 (https=)
CN (1) CN101180296B (https=)
AR (1) AR053730A1 (https=)
AT (1) ATE452133T1 (https=)
AU (1) AU2006246669B2 (https=)
BR (1) BRPI0610320A2 (https=)
CA (1) CA2609288C (https=)
DE (1) DE602006011156D1 (https=)
DK (1) DK1888567T3 (https=)
DO (1) DOP2006000119A (https=)
ES (1) ES2338151T3 (https=)
GT (1) GT200600211A (https=)
IL (1) IL187430A (https=)
MX (1) MX2007014274A (https=)
MY (1) MY150693A (https=)
PA (1) PA8675301A1 (https=)
PE (1) PE20061452A1 (https=)
PT (1) PT1888567E (https=)
SV (1) SV2007002534A (https=)
TW (1) TWI376377B (https=)
UY (1) UY29550A1 (https=)
WO (1) WO2006122661A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149102A1 (en) * 2011-04-29 2012-11-01 Glaxosmithkline Llc Novel compounds as wip1 inhibitors
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9520044B (sl) 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
HUP0304058A2 (hu) * 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
EP1590327A1 (en) * 2002-12-23 2005-11-02 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
TW200510311A (en) * 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
JP4585448B2 (ja) * 2002-12-23 2010-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 第Ｘａ因子阻害剤としてのピラゾール−誘導体
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Also Published As

Publication number Publication date
DE602006011156D1 (de) 2010-01-28
DK1888567T3 (da) 2010-04-19
CA2609288A1 (en) 2006-11-23
DOP2006000119A (es) 2006-11-30
KR20080015800A (ko) 2008-02-20
PT1888567E (pt) 2010-02-09
JP5027802B2 (ja) 2012-09-19
US8088925B2 (en) 2012-01-03
ES2338151T3 (es) 2010-05-04
PA8675301A1 (es) 2006-12-07
TW200716620A (en) 2007-05-01
ATE452133T1 (de) 2010-01-15
AR053730A1 (es) 2007-05-16
GT200600211A (es) 2007-02-05
UY29550A1 (es) 2006-12-29
BRPI0610320A2 (pt) 2010-06-15
EP1888567A1 (en) 2008-02-20
AU2006246669B2 (en) 2011-10-06
SV2007002534A (es) 2007-02-19
EP1888567B1 (en) 2009-12-16
CN101180296A (zh) 2008-05-14
US20080167346A1 (en) 2008-07-10
KR101373533B1 (ko) 2014-03-12
EP1724269A1 (en) 2006-11-22
MX2007014274A (es) 2008-01-22
IL187430A0 (en) 2008-02-09
JP2008540589A (ja) 2008-11-20
CA2609288C (en) 2014-01-21
PE20061452A1 (es) 2007-01-16
WO2006122661A1 (en) 2006-11-23
AU2006246669A1 (en) 2006-11-23
CN101180296B (zh) 2011-10-19
HK1117157A1 (en) 2009-01-09
MY150693A (en) 2014-02-28
TWI376377B (en) 2012-11-11

Similar Documents

Publication Publication Date Title
IL274602B (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and their use in the preparation of drugs for the treatment of thrombocytopenia
IL210452A (en) Annotations of dimethyl-oxo-dihydro- (pyridine-3-or-4-ram) -phenyl-6-methyl-6-phenyl- [1,3] -oxiazine-2-one
WO2008003766A3 (en) 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
IL181524A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL189375A (en) Derivatives 1-Heterocyclicsulfonyl-3-Aminomethyl-5- (hetero-) aryl-1-h- Pyrol
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
IL204052A (en) Annotation of 1,1,1 - Tripluoro - 2 - Hydroxy - 3 - Phenylpropane
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL196775A (en) Annotations 4,2-Bis (3-Methyl-Morpholine-4-Yl) -7-Phenyl-Pyrido [3,2- d] Pyrimidine, Containing and Using Pharmaceuticals as Drugs and Drug Manufacturing
TW200640908A (en) Chemical compounds
IL199835A (en) Acid-activated antimicrobial peptides, their pharmaceutical preparations, and their use in drug preparation
IL184712A (en) History of pyrzulo-pyrimidine, process of preparation, medicinal preparations containing them and use of pharmaceutical preparations
EP1865967A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
UA95715C2 (ru) Фосфадиазиновые производные, фармацевтическая композиция и их применение
IL196653A (en) Kempthetine derivatives, preparations containing them, their uses for drug preparation and processes for their preparation
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
IL196891A (en) Annals @@@ - Amino - @@@@@@@ - Tetrahydro - H9 - Carbazole - 9 - Yl) - Acetic Acid, Containing Pharmaceuticals
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
IL208355A (en) Annotations 7,3-Dihydroporin-6,2-Discussion, Processes for their Preparation, Pharmaceutical Preparations Containing them and their Use in Medication Preparation
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
IL191310A (en) A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases
IL181022A0 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees